Lower concentration of serum soluble CD8 in severe Hashimoto's disease

Clinical and Experimental Immunology

Volumn 137, Issue 3, 2004, Pages 601-605

  Yamamoto, N ^a,c   Watanabe, M ^a   Matsuzuka, F ^b   Miyauchi, A ^b   Iwatani, Yoshinori ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KUMA HOSPITAL   (Japan)

^c SARAYA CO LTD   (Japan)

Author keywords

Autoimmune disease; Cytotoxic T cell; Intractability; Severity; Soluble protein

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR; MICROSOME ANTIBODY; MONOCLONAL ANTIBODY; THYROGLOBULIN ANTIBODY; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FREE LIOTHYRONINE INDEX; GOITER; HASHIMOTO DISEASE; HUMAN; HUMAN CELL; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SERUM; THYROTOXICOSIS;

ANTIGENS, CD4; ANTIGENS, CD8; CASE-CONTROL STUDIES; FEMALE; GRAVES DISEASE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTE SUBSETS; THYROID FUNCTION TESTS; THYROID HORMONES; THYROIDITIS, AUTOIMMUNE;

EID: 4344691192     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02576.x     Document Type: Article

References (29)

1. Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994; 15:788-830.
2. Weetman AP. Autoimmune thyroid disease. In: Weetman AP, ed. Autoimmune Endocrine Disease. Cambridge: Cambridge University Press, 1991:66-161.
3. Volpe R. The immune system and its role in endocrine function. In: Becker KL, ed. Principles and Practice of Endocrinology and Metabolism. Philadelphia: Lippincott, Williams & Wilkins, 2001, 1770-81.
4. + cells and thyroid autoantibodies in disease severity of Hashimoto's disease. Thyroid 2002; 12:801-8.
5. Watanabe M, Yamamoto N, Maruoka H et al. Relation of CD30 molecules on T-cell subsets to the severity of autoimmune thyroid disease. Thyroid 2003; 13:259-63.
6. Nakamoto Y, Niki M, Watanabe M, Iwatani Y. Increase in immunoglobulin G3-secreting cells in intractable Graves' disease. Thyroid 2003; 13:325-31.
7. Littman DR. The structure of the CD4 and CD8 genes. Annu Rev Immunol 1987; 5:561-84.
8. Ehlers MR, Riordan JF. Membrane proteins with soluble counter-parts: role of proteolysis in the release of transmembrane proteins. Biochemistry 1991; 30:10065-74.
9. Symons JA, Wood NC, di Giovine FS, Duff GW. Soluble CD8 in patients with rheumatic diseases. Clin Exp Immunol 1990; 80:354-9.
10. Symons JA, McCulloch JF, Wood NC, Duff GW. Soluble CD4 in patients with rheumatoid arthritis and osteoarthritis. Clin Immunol Immunopathol 1991; 60:72-82.
11. Sawada S, Hashimoto H, Iijima S et al. Immunologic significance of increased soluble CD8/CD4 molecules in patients with active systemic lupus erythematosus. J Clin Laboratory Anal 1993; 7:141-6.
12. Tomkinson BE, Brown MC, Ip SH, Carrabis S, Sullivan JL. Soluble CD8 during T cell activation. J Immunol 1989; 142:2230-6.
13. Griffin DE, Ward BJ, Jauregui E, Johnson RT, Vaisberg A. Immune activation in measles. N Engl J Med 1989; 320:1667-72.
14. Watanabe M, Amino N, Hochito K et al. Opposite changes in serum soluble CD8 in patients at the active stages of Graves' and Hashimoto's diseases. Thyroid 1997; 7:743-7.
15. Sewell AK, Gerth UC, Price DA et al. Antagonism of cytotoxic T-lymphocyte activation by soluble CD8. Nat Med 1999; 5:399-404.
16. - cells, in autoimmune thyroid disease. Clin Exp Immunol 1993; 93:430-6.
17. Balazs C, Bokk A, Farid NR. Serum soluble CD8 concentration is an indicator of disease activity in patients with Graves' disease. Thyroid 1994; 4:27-30.
18. + T cells. J Exp Med 1997; 186:1407-18.
19. + type 1 cytotoxic T cells both play a crucial role in the full development of contact hypersensitivity. J Immunol 2000; 165:6783-90.
20. Miyazaki A, Shimura H, Endo T, Haraguchi K, Onaya T. Tumor necrosis factor-alpha and interferon-gamma suppress both gene expression and deoxyribonucleic acid-binding of TTF-2 in FRTL-5 cells. Endocrinology 1999; 140:4214-20.
21. Ohe K, Ikuyama S, Takayanagi R, Kohn LD, Nawata H. Interferon-gamma suppresses thyrotropin receptor promoter activity by reducing thyroid transcription factor-1 (TTF-1) binding to its recognition site. Mol Endocrinol 1996; 10:826-36.
22. Murphy ED, Kallio P. Soluble CD antigen (cytokine) expression in various hyperthyroid states and use in the assessment of propylthiouracil treatment. J Laboratory Clin Med 1994; 124:255-62.
23. Itoh M, Uchimura K, Yamamoto K et al. Distinctive response of thyroid-infiltrating mononuclear cells to B cell activation through CD40 and interleukin-4 in Graves' patients. Cytokine 2002; 19:107-14.
24. Watanabe M, Iwatani Y, Hidaka Y, Mitsuda N, Amino N. Changes in soluble CD4 and CD8 proteins in healthy pregnant and postpartum women. Am J Reprod Immunol 1996; 36:220-7.
25. Yoneyama A, Nakahara K, Higashihara M, Kurokawa K. Increased levels of soluble CD8 and CD4 in patients with infectious mononucleosis. Br J Haematol 1995; 89:47-54.
26. Sawada S, Sugai S, Iijima S et al. Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjogren's syndrome. Am J Med 1992; 92:134-40.
27. Sun CC, Wu J, Wong TT, Wang LF, Chuan MT. High levels of interleukin-8, soluble CD4 and soluble CD8 in bullous pemphigoid blister fluid. The relationship between local cytokine production and lesional T-cell activities. Br J Dermatol 2000; 143:1235-40.
28. Klappacher G, Mehrabi M, Plesch K et al. Serum-soluble CD4 as clinical and immunological marker in patients with dilated cardiomyopathy. Immunol Lett 1993; 38:103-9.
29. Amino N, Tada H, Hidaka Y. Postpartum autoimmune thyroid syndrome: a model of aggravation of autoimmune disease. Thyroid 1999; 9:705-13.